New cell therapy tested for Tough-to-Treat gynecologic cancers
NCT ID NCT06342986
Summary
This early-stage study is testing a new cell therapy called FT536 for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. The therapy involves collecting and modifying a patient's own immune cells, then giving them back directly into the abdomen. The main goal is to see if this approach is safe and can help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Minnesota Masonic Cancer Center
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.